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JMF2-1Inhalation of JMF2-1, an analog of lidocaine with reduced anesthetic activity, prevents airway contraction and
lung inﬂammation in experimental asthma models. We sought to test if the JMF2-1 effects are a consequence
of increased intracellular cAMP levels in asthma cell targets, such as smoothmuscle cells and T cells. Function-
al effect of JMF2-1 on carbachol-induced contraction of intact or epithelial-denuded rat trachea was assessed
in conventional organ baths. cAMP was quantiﬁed by radioimmunoassay in cultured guinea pig tracheal
smooth muscle cells, as well as lymph node cells from BALB/c mice, exposed to JMF2-1. We found that
JMF2-1 (0.1–1 mM) concentration-dependently inhibited epithelium-intact tracheal ring contraction induced
by carbachol challenge. The antispasmodic effect remained unaltered following epithelium removal or
pretreatment with NG-nitro-L-arginine methyl ester (100 μM), but it was clearly sensitive to 9-(tetrahydro-
2-furyl) adenine (SQ22,536, 100 μM), an adenylate cyclase inhibitor. JMF2-1 (300 and 600 μM) also dose-
dependently increased cAMP intracellular levels of both cultured airway smooth muscle cells and T
lymphocytes. This effect was consistently abrogated by SQ22,536 and reproduced by forskolin in both systems.
JMF2-1 induced apoptosis of anti-CD3 activated T cells in a mechanism sensitive to zIETD, indicating that
JMF2-1 mediates caspase-8-dependent apoptosis. Furthermore, forskolin also inhibited anti-CD3 induced T cell
proliferation and survival. Our results suggest that JMF2-1 inhibits respiratory smooth muscle contraction as
well as T cell proliferation and survival through enhancement of intracellular cAMP levels. These ﬁndings may
help to explain the anti-inﬂammatory and antispasmodic effects of JMF2-1 observed in previous studies.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Asthma is a chronic lung inﬂammatory disease characterized by
airway hyperresponsiveness and lung inﬂammation, generally
marked by eosinophil and lymphocyte inﬁltration (Barnes, 2004;
Moore, 2008). Combination of a bronchodilator with glucocorticoids,
can successfully control most of the patients, but a minority of them
are resistant to this conventional therapy (Adcock et al., 2008).
The local anesthetic lidocaine has been used as an alternative ther-
apy to control asthma symptoms in patients that respond poorly to
classical glucocorticoid treatment (Hunt et al., 2004; Saito et al.,
2006). However, the safety and usefulness of lidocaine are debatable
since some patients demonstrated irritation of the airways and initial
bronchoconstriction, which were associated with its local anesthetic
activity (Burches and Warner, 2008; Harrison and Tattersﬁeld,
1998; Hirota et al., 1999).
We have recently reported the pharmacological properties of lido-
caine analogs synthesized and screened for reduced local anesthetiction, Oswaldo Cruz Institute,
Manguinhos, CEP. 21045-900,
55 21 25587382.
ins).
evier OA license.activity. Changes in the aromatic ring of lidocaine led to JMF2-1 (2-
diethylamine-2′-triﬂuormethyl-acetoanilide hydrochloride) (Fig. 1),
an analog able to combine reduced local anesthetic activity with in-
creased antispasmodic and anti-inﬂammatory properties (Costa et
al., 2008; da Costa et al., 2007). Nebulization with JMF2-1 is a way
of achieving the anti-asthma properties of lidocaine without anesthe-
sia, encouraging further research on the mechanism of action and pu-
tative therapeutic application of JMF2-1. Our previous study showed
that JMF2-1 prevents ovalbumin (OVA) induced lung inﬂammation
and airway hyperresponsiveness by inhibiting activation and survival
of T cells (Olsen et al., 2011).
Since the mode of action of JMF2-1 remained poorly understood,
the aim of this study was to investigate the molecular mechanisms
by which JMF2-1 reduces inﬂammation and bronchospasm.2. Material and methods
2.1. Animals
Male guinea pigs (300–400 g) and Wistar rats (250–350 g), as
well as BALB/c (18–20 g) and DO11.10 TCR Tg mice were obtained
from the Oswaldo Cruz Foundation breeding colonies (Rio de Janeiro,
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N
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Fig. 1. Chemical structure of JMF2-1.
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examined and approved by the Animal Ethics Committee of Oswaldo
Cruz Foundation (CEUAFIOCRUZ, LW-23/10), Rio de Janeiro, Brazil.
2.2. Chemicals
JMF2-1.HCl was synthesized in the Department of Organic Synthe-
sis of Far-Manguinhos (FIOCRUZ, Rio de Janeiro, RJ, Brazil) from 2-
triﬂuormethyl-aniline, with a chromatography purity of >99.8%
(Fig. 1). OVA (grade-V), Nω-nitro-l-arginine methyl ester (L-NAME),
Propranolol, Forskolin, SQ22,536 and IBMX were purchased from
Sigma–Aldrich (St. Louis, MO, USA). JMF2-1 and Propranolol were
dissolved in sterile saline solution immediately before use. Forskolin,
SQ22,536 and IBMX were freshly prepared in DMSO (ﬁnal concentra-
tion of 0.1%).
2.3. T cell apoptosis and proliferation
Pooled cervical, axial and inguinal lymph node cells (106/well)
obtained from naïve DO11.10 TCR Tg mice were pre-treated with
50 μM zIETD.fmk (Calbiochem, San Diego, USA) for 1 h before stimu-
lation with OVA (0.5 mg/ml) and exposure to 300 μM JMF2-1. Treat-
ments lasted 72 h at 37 °C in an atmosphere of 5% CO2. Apoptosis
was assessed as previously described (Olsen et al., 2011).
Pooled cervical, axial and inguinal lymph node cells (106/well)
from BALB/c mice were stimulated with anti-CD3 (10 mg/ml) (BD
Biosciences Pharmingen) and treated with either 300 μM JMF2-1 or
100 μM forskolin for 72 h at 37 °C in an atmosphere of 5% CO2. Prolif-
erating values and DNA fragmentation of retrieved cells were ana-
lyzed by permeabilizing and staining cells with propidium iodide
(PI), as previously described (Olsen et al., 2011).
2.4. cAMP intracellular levels in T lymphocytes and airway smooth
muscle cells
Intracellular cAMP concentrations were assayed in primary cul-
tured guinea-pig tracheal smooth muscle cells as previously de-
scribed (Wu et al., 2001). Brieﬂy, smooth muscle cells obtained
from guinea pig tracheas were cultured in DMEM containing 10%
fetal bovine serum, 100 units/ml of penicillin, 100 mg/ml of strepto-
mycin and 2 mM of glutamine for 3 to 7 days. After the third cell split-
ting, 106 cells/well were grown in 24-well plates. At conﬂuence,
monolayer cells were washed with PBS and incubated with JMF2-1
(10–1000 μM) or 100 μM forskolin (adenylate cyclase activator), in
the presence or absence of 100 μM SQ22,536 (adenylate cyclase in-
hibitor) for 30 min. All incubations were done in the presence of
100 μM IBMX, a phosphodiesterase inhibitor. Lysed cells were collect-
ed and the cAMP was determined by using a radioimmunoassay kit
(TRK 432–Cyclic AMP[3H] Biotrak assay system—Amersham Pharma-
cia Biotech, Buckinghamshire, England).Intracellular cAMP levels in lymphocytes were also analyzed.
Pooled cervical, axial and inguinal lymph node cells (106/well) from
BALB/c mice were stimulated with 10 μg/ml anti-CD3 (Pharmingen)
and treated with JMF2-1 (100, 300 and 600 μM) or forskolin
(100 μM), in the presence or absence of 100 μM SQ22,536, for
20 min. All incubations were done in the presence of 100 μM IBMX.
Lymphocytes were lysed and cAMP levels were measured as de-
scribed above.
2.5. Isolated tracheal preparation and measurement of tension
Tracheas from Wistar rats were prepared as described previously
(Coelho et al., 2008). Brieﬂy, animals were killed in a CO2 atmosphere
and tracheas were quickly immersed in Krebs' nutritional solution
(118 mM NaCl, 4.8 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 1.2 mM
KH2PO4, 24 mMNaHCO3, and 11 mM glucose). Tracheas were dissect-
ed then cut into rings. These tracheal rings were mounted in isolated
organ baths ﬁlled with 10 ml of Krebs' solution, maintained at 37 °C,
and aerated with 95% O2 and 5% CO2. To achieve a steady spontaneous
tone level, an initial tension of 1 g was applied. Contractions were
measured isometrically with a force–displacement transducer (Ugo
Basile, Comerio, Italy) and recorded by an Isolated Organs Data Acqui-
sition program (Proto5; Letica Scientiﬁc Instruments, Barcelona,
Spain). Tissues were allowed to stabilize for 60 min, whereas the
bathing solution was exchanged at 10-min intervals. At the end of
the equilibration period, the response to 2.5 μM carbachol was
recorded. After washout of carbachol and re-establishment of stable
baseline tone, tissues were re-exposed to carbachol (10−8–10−4 M)
in the presence or absence of JMF2-1 (100, 300 and 1000 μM) or lido-
caine (300 and 1000 μM). The preparations were preincubated with
JMF2-1 or lidocaine 15 min before addition of the spasmodic agent.
All responses were expressed as percentages of the response to
2.5 μM carbachol.
In a particular experiment, the epithelial cells were removed me-
chanically as described previously (Coelho et al., 2008). During the
experiment, the contractile response to 2.5 μM carbachol was mea-
sured before and after a 15-min exposure to 1000 μM JMF2-1 of intact
or denuded epithelium tracheal rings. To further investigate the
mechanisms of action of JMF2-1, the tracheal rings were pretreated
10 min before its application with 100 μM L-NAME (nitric-oxide
synthase inhibitor), 100 μM SQ22,536 or 1 μM propranolol (β2-recep-
tor blocker).
2.6. Statistical analyses
Statistical analyses were done with ANOVA followed by the New-
man–Keuls–Student test. Pb0.05 (two-tailed test) was considered
signiﬁcant.
3. Results
3.1. Effect of JMF2-1 on rat tracheal contractions induced by carbachol
Fig. 2 shows the cumulative concentration–response curves of rat
tracheal rings triggered by increasing concentrations of carbachol
(10−8–10−4 M) against either JMF2-1 (100–1000 μM) (part A) or li-
docaine (300 and 1000 μM) (part B). Notably, the pre-treatment with
JMF2-1 signiﬁcantly reduced, in a concentration-dependent manner,
the maximal contractile response elicited by carbachol, inhibiting
the maximal effect of contraction in 67.0%±1.9% (n=8) at the high-
est concentration, as it shifted the concentration–response curves for
carbachol to the right. In contrast, the prototype lidocaine shifted the
carbachol response to the right and signiﬁcantly inhibited its maximal
response (15.2%±0.9%, n=8) only at the highest concentration
tested.
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Fig. 2. JMF2-1 induces rat tracheal relaxation. Anti-spasmodic effects of JMF2-1
(100–1000 μM) (Part A) and lidocaine (300 and 1000 μM) (Part B) on the rat tracheal
contraction induced by carbachol. Each point represents the mean±S.E.M. of eight ex-
periments. All results were expressed as a percentage of contractile responses induced
by 2.5 μM carbachol. *Pb0.05 compared with tracheal responses from vehicle-treated
preparations. +Pb0.05 compared with tracheal responses from JMF2-1-treated
preparations.
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cyclase in the antispasmodic effect of JMF2-1
We studied whether the epithelium would be implicated in the
effect of JMF2-1 by mechanically removing the epithelial cells of
the internal tracheal surface as reported previously (Coelho et al.,
2008). The results showed that JMF2-1 equally inhibited
carbachol-induced tracheal contraction in the presence or absence
of epithelium as shown in Fig. 3A. This protective response also
remained unaltered following pretreatment with 100 μM L-NAME,
as added to the medium 10 min before exposure to JMF2-1
(Fig. 3B). In contrast, the protective effect of JMF2-1 upon
carbachol-induced contractile responses was clearly sensitive to
the pretreatment with the adenylate cyclase inhibitor 100 μM
SQ22,536, as shown in Fig. 3C. In addition, propranolol pre-
treatment did not change the antispasmodic activity of JMF2-1 as
shown in Fig. 3D.3.3. JMF2-1 increases intracellular cAMP levels in airway smooth muscle
cells
To check the impact of JMF2-1 treatment on the adenylate cyclase/
cAMP pathway, we studied the pattern of the intracellular cAMP
levels of primary cultured smooth muscle cells in the absence or pres-
ence of increasing concentrations of JMF2-1 (10–1000 μM). As
expected, forskolin signiﬁcantly enhanced cAMP levels in these cells
(Fig. 4). Similarly, JMF2-1 (100 and 1000 μM) increased concentration
dependently the intracellular cAMP content, an effect which was
clearly abrogated by pretreatment with the adenylate cyclase inhibi-
tor SQ22,536 (100 μM). No changes in cAMP levels were noted be-
tween untreated and DMSO-treated groups (data not shown).
3.4. T cell apoptosis induced by JMF2-1 is mediated by caspase-
8 activation
We have previously shown that JMF2-1 induces caspase-
dependent apoptosis of T cells (Olsen et al., 2011). Since increase in
intracellular cAMP levels in T cells has led to caspase-8 activation
and blockade of cytokine secretion (Naderi and Blomhoff, 2008), we
sought to investigate whether JMF2-1 would activate the extrinsic
(Fas-mediated) apoptotic pathway. Lymph node cells from naïve
DO11.10 mice were pre-treated with the caspase-8 inhibitor 50 μM
zIETD for 1 h and then exposed to ovalbumin (0.5 mg/ml) in the pres-
ence or absence of 300 μM JMF2-1 for 72 h. As noted in Fig. 5, zIETD
prevented the pro-apoptotic effect of JMF2-1.
3.5. Adenylate cyclase activation enhances apoptosis and inhibits prolif-
eration in T cells from mice
As demonstrated before in Jurkat human cells, cAMP elevation in-
duced by an adenylate cyclase activator, forskolin, potentiates Fas-
induced apoptosis (Naderi and Blomhoff, 2008). Similar to JMF2-1,
forskolin induces both apoptosis (Fig. 6A) and blockade of prolifera-
tive response (Fig. 6B) of T cell following anti-CD3 stimulation.
3.6. JMF2-1 increases intracellular cAMP levels in anti-CD3 stimulated T
cells
Since elevation of cAMP levels has been implicated in the inhibi-
tion of T lymphocyte activity and survival (Bjorgo and Tasken, 2006;
Naderi and Blomhoff, 2008; Vendetti et al., 2006), we looked further
at the generation of cAMP by anti-CD3 stimulated lymph node T
cells following exposure to increasing concentrations of JMF2-1. As
indicated in Fig. 7, treatment with JMF2-1 (100–600 μM) for 30 min
induced a concentration-dependent increase in the intracellular
cAMP levels of anti-CD3-stimulated T cells, in a mechanism clearly
sensitive to the adenylate cyclase inhibitor SQ22,536 (100 μM). For-
skolin also led to cAMP upregulation which was, as expected, pre-
vented by SQ22,536 (Fig. 7). No changes in cAMP levels were noted
between untreated and DMSO-treated groups (data not shown).
4. Discussion
In the current study, we demonstrate that the non-anesthetic lido-
caine analog JMF2-1 leads to an adenylate cyclase-dependent in-
crease in the intracellular levels of cAMP in both airway smooth
muscle cells and activated T lymphocytes. In line with this data, the
adenylate cyclase inhibitor SQ22,536 partially prevents the antispas-
modic effect of JMF2-1 on carbachol-induced tracheal ring contrac-
tion. Furthermore, we show that JMF2-1 treatment increases cAMP
intracellular levels on anti-CD3 stimulated T cells, which might be as-
sociated with the induction of apoptosis and the reduction of activity
of lymphocytes induced by JMF2-1. These ﬁndings support the
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Fig. 4. JMF2-1 increases intracellular cAMP levels in airway smooth muscle cells. Effect
of JMF2-1 (10–1000 μM) treatment on guinea pig tracheal smooth muscle cells cAMP
intracellular levels. Cells were treated for 20 min with either JMF2-1 or forskolin in
the presence or absence of SQ22,536. Values represent the mean±S.E.M (n=3) (rep-
resentative of two experiments). *Pb0.05 as compared to untreated cells.
0
20
40
60
80
100
*
#
+
OVA
JMF2-1
zIETD
-
-
-
+
-
-
+
+
-
+
+
+
%
 c
el
ls
 in
 S
ub
-G
0
Fig. 5. Apoptosis induced by JMF2-1 is dependent on caspase-8 activation. Effect of
JMF2-1 (300 μM) on the sub-diploid DNA content (sub-G0/G1) of lymph node cells,
obtained from DO11.10 mice, stimulated with OVA (0.5 mg/ml) in the presence or ab-
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Fig. 6. Forskolin induces apoptosis and inhibition of proliferation of T cells in vitro. Ef-
fect of forskolin (100 μM) on the subdiploid DNA (sub-G0/G1) content (A) and prolifer-
ation (B) of lymph node cells recovered from BALB/c mice subjected to stimulation
with anti-CD3. The percentage of cells undergoing DNA fragmentation and cell prolif-
eration was determined by propidium iodide staining (ﬂow cytometry) performed
within 72 h after exposure to anti-CD3. Values represent mean±SEM from three
mice (representative of 3 experiments). +Pb0.05 as compared with saline-stimulated
lymph node cells. *Pb0.05 as compared with anti-CD3-stimulated but untreated cells.
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levels to promote relaxant and anti-inﬂammatory responses.
Drugs able to prevent airway obstruction and/or inﬂammation
have potential to beneﬁt asthmatic patients. Remarkably, the local an-
esthetic lidocaine shows signiﬁcant effects as an anti-inﬂammatory
and anti-spasmodic agent, and several clinical studies demonstrated
that nebulized lidocaine is indeed beneﬁcial in asthma therapy
(Decco et al., 1999; Groeben et al., 1999; Hunt et al., 2004; Saito et
al., 2006; Siqueira et al., 2005). Since lidocaine is known by its ability0
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Fig. 7. JMF2-1 increases intracellular cAMP levels in anti-CD3 stimulated T cells. Effect
of JMF2-1 (100–600 μM) treatment on cAMP intracellular level of T cells stimulated
with anti-CD3 (10 μg/ml). Antigenic stimulated cells were treated for 30 min with ei-
ther JMF2-1 or forskolin in the presence or absence of SQ22,536. Values represent
the mean±S.E.M (pooled lymph node cells, n=3) (representative of two experi-
ments). *Pb0.05 as compared to anti-CD3-stimulated but untreated cells.to inhibit voltage-dependent sodium channels, it is tempting to as-
sume that lidocaine is working by inhibiting neural regulation of in-
ﬂammation and respiratory smooth muscle contraction. However,
there are mounting evidence that these alternative actions result
from lidocaine interacting with targets other than excitable cells
and sodium channels (Bankers-Fulbright et al., 1998; Hollmann and
Durieux, 2000; Kai et al., 1993; Okada et al., 1998). JMF2-1 is a non-
anesthetic lidocaine analog able to inhibit crucial pathological fea-
tures of asthma, including allergen-induced smooth muscle contrac-
tion, airway hyper-reactivity and leucocyte inﬁltration (eosinophils,
CD4 T cells) into the lung (Costa et al., 2008; da Costa et al., 2007;
Olsen et al., 2011). But, what are the possible mechanisms by which
this occurs? Because the second messenger cAMP is responsible for
different signaling pathways in several inﬂammatory and structural
cells, including T lymphocytes and airway smooth muscle cells, we
sought to test the hypothesis that JMF2-1 is modulating the function
of these cells by increasing the intracellular concentration of cAMP.
Prior studies demonstrated that lidocaine prevents muscarinic
receptor-mediated inhibition of adenylate cyclase in the airway
smooth muscle, and exert a synergistic effect on the responses to
agents that activate this enzyme (such as β2-agonists and forskolin)
under conditions of cholinergic bronchoconstriction (Nakahara et
al., 2000; Yunoki et al., 2003). Elevation of intracellular cAMP leads
to relaxation of airway smooth muscle via several actions, such as in-
tracellular Ca2+ sequestration (Mueller and van Breemen, 1979), ac-
tivation of Ca2+-dependent K+ channels (Kume et al., 1989),
inhibition of inositol phospholipid hydrolysis (Hall et al., 1989) and
decrease in the sensitivity of contractile proteins to Ca2+ (Abe and
Karaki, 1992; Bai and Sanderson, 2006; Oguma et al., 2006). Further-
more, it is well established that lidocaine blocks contraction evoked
by muscarinic receptors by inhibiting Ca2+ inﬂux and decreasing
the sensitivity of contractile protein to Ca2+ (Kai et al., 1993). In the
current study we demonstrated that JMF2-1 presented a higher po-
tency and higher efﬁcacy to inhibit carbachol-induced rat tracheal
contraction as compared to lidocaine, and similar effects were noted
when mice and guinea pig trachea rings were assessed (data not
shown). These ﬁndings are consistent with those in which the con-
tractile response caused by allergen provocation or by increasing ex-
tracellular Ca2+ concentration following high K+ depolarization,
were more sensitive to JMF2-1 than to lidocaine (da Costa et al.,
2007), suggesting that this non-anesthetic lidocaine analog may be
indeed a hit for optimized spasmolytic agents.
We have shown, in the current work, that the protective effect of
JMF2-1 on the carbachol-induced contraction of rat tracheal rings
was neither modiﬁed by epithelium removal nor by pretreatment
with the nitric-oxide synthase inhibitor L-NAME, discarding the in-
volvement of nitric oxide and other epithelium-derived relaxing fac-
tors in this effect. It is noteworthy that similar ﬁndings have been
reported for lidocaine and bupivacaine (Lautner et al., 2009). In con-
trast, the antispasmodic effect of JMF2-1 was shown to be inhibited
by pretreatment with the adenylate cyclase blocker SQ22,536. This
ﬁnding led us to investigate whether JMF2-1 could directly up-
regulate cAMP in cultured airway smooth muscle cells. Yunoki et al.
(2003) reported that lidocaine enhanced basal and forskolin-
stimulated cAMP accumulation in bovine tracheal tissue, but only
under condition of co-stimulation with methacholine. According to
these authors, lidocaine acts in this system by attenuating the inhibi-
tion of adenylate cyclase induced by the muscarinic receptor agonist
(Yunoki et al., 2003). In contrast, our data revealed that JMF2-1,
concentration-dependently, enhanced the basal cAMP concentration
in primary cultured smooth muscle cells derived from guinea pig tra-
cheas, even in the absence of muscarinic stimulation. Since the phe-
nomenon was abrogated by blockade of adenylate cyclase, JMF2-1
may be acting directly or indirectly through the adenylate cyclase
pathway. While trying to clarify whether the cAMP-dependent
smooth muscle relaxation elicited by JMF2-1 derives from a β2
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ceptor blocker propranolol, but such a treatment failed to alter the
JMF2-1 anti-spasmodic effect. Assuming that the β2-receptor is irrel-
evant for the JMF2-1 relaxation property, one cannot discard the pos-
sibility that JMF2-1 may act, like forskolin, through a direct activation
of adenylate cyclase.
A previous study has demonstrated that lidocaine inhibits T cell
function and cytokine production without inducing apoptosis of
these cells (Tanaka et al., 2002). Although lidocaine does not seem
to reduce inﬂammation by stimulating lymphocyte apoptosis, the li-
docaine analog JMF2-1 showed pro-apoptotic effect on T cells both
in vitro and in vivo (Olsen et al., 2011). In order to assess if the lym-
phocyte pro-apoptotic activity of JMF2-1 may account for its ability to
reduce the functional activity of these cells, we have used the
caspase-8 inhibitor, zIETD, before anti-CD3 stimulation. Under this
condition, zIEDT prevented the pro-apoptotic effect of the lidocaine
analog, supporting the interpretation that JMF2-1 acts via caspase-8,
eliciting the Fas-dependent extrinsic pathway of apoptosis.
Transient increase in cAMP intracellular levels occurs in T cells fol-
lowing TCR antigenic activation, and this event further inhibits cell
signaling, unless there is co-stimulation, which induces a reduction
in cAMP intracellular levels, allowing the ampliﬁcation of the signal-
ing induced by the antigenic challenge (Bjorgo and Tasken, 2006;
Vendetti et al., 2006). There is evidence in the literature that an in-
crease in cAMP intracellular levels causes a reduction of proliferation
and IL-2 production in T cells. In addition, it increases the expression
of the inhibitory molecule CTLA-4 and induces anergy in resting T
cells (Vendetti et al., 2006). Continuous rise in cAMP intracellular
levels in T lymphocytes is also associated with the activation of
caspase-8 and inhibition of the cell functional activity (Naderi and
Blomhoff, 2008). In line with previous ﬁndings (Naderi and
Blomhoff, 2008), we demonstrated here that up-regulation of cAMP
concentration by forskolin is associated with blockade of anti-CD3-
stimulated proliferation and survival of mouse lymph node T cells. It
is noteworthy that JMF2-1 was also able to inhibit cell proliferation
and enhance apoptosis of T-cells from BALB/c mice stimulated by
anti-CD3 similar to forskolin (Olsen et al., 2011). Moreover, we dem-
onstrated that, similar to what was observed in case of airway smooth
muscle cells, JMF2-1 increased the cAMP content of T lymphocytes, in
a mechanism entirely dependent on adenylate cyclase activity.
In conclusion, these data show that JMF2-1 acts by increasing
cAMP concentrations in T lymphocytes and smooth muscle cells lead-
ing to two unique effects: a caspase-8 dependent down-regulation of
T lymphocytes survival, and relaxation of airway smooth muscle cells.
Altogether, these ﬁndings help to explain the anti-inﬂammatory and
anti-spasmodic effects of JMF2-1 observed in several experimental
asthma systems.
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